Prescription opioid abuse is the fastest growing form of opiate/opioid abuse in the United States. Most of these medications come from prescriptions written for pain. There is controversy as to the risk of abuse and addiction when chronic non-malignant pain is treated by prescription opioids. The risk of developing abuse or addiction has never been studied in a longitudinal fashion among patients of primary care physicians who initiate most of the opioid treatment. Some experts advise against the use of opioid analgesics in this population because they believe that tolerance soon renders the medication ineffective and the risk of addiction is high while others say that addiction is rare among pain patients and that analgesia continues over time. Neither side has longitudinal studies with appropriate measures to support their arguments. In any case, the medications are being widely prescribed because pain is ubiquitous and the physicians who initiate the greatest number of patients on this treatment are primary care physicians. We propose to study the treatment of pain in a large sample (600 patients) of typical primary care patients who are ethnically diverse to determine whether pain relief continues over 24 months and what is the frequency of aberrant behaviors leading to abuse or addiction. End points will be based on the DSM diagnosis of abuse or addiction. We will carefully measure baseline factors that are thought to increase risk of addiction such as history of substance abuse, family history and presence of psychiatric disorders such as depression and anxiety. We will also monitor prescribing practices of the 92 primary care physicians who have volunteered to be included in the study. Patients with a history of substance abuse will not be excluded because these patients also have chronic pain and at present there are no evidence-based guidelines on the increased risk of abuse posed by these patients nor what methods can be used to treat their pain adequately without the appearance of abuse or relapse. Our ultimate goal is the prevention of abuse and the improvement of pain treatment. During the final year of this five year project, we will begin to apply the information learned from the longitudinal study to develop a package of treatment guidelines that can be tested in a subsequent randomized, controlled trial against treatment as usual (as defined by our observational study). These treatment guidelines, tailored to the needs of primary care physicians, will be disseminated in meetings and journals as described in our current program to bring awareness of substance abuse to mainstream medicine.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Comprehensive Center (P60)
Project #
5P60DA005186-23
Application #
7862443
Study Section
Special Emphasis Panel (ZDA1)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
23
Fiscal Year
2009
Total Cost
$518,865
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Franklin, Teresa R; Jagannathan, Kanchana; Hager, Nathan et al. (2018) Brain substrates of early (4h) cigarette abstinence: Identification of treatment targets. Drug Alcohol Depend 182:78-85
Wetherill, Reagan R; Jagannathan, Kanchana; Hager, Nathan et al. (2016) Influence of menstrual cycle phase on resting-state functional connectivity in naturally cycling, cigarette-dependent women. Biol Sex Differ 7:24
Woody, George E; Krupitsky, Evgeny; Zvartau, Edwin (2016) Antagonist Models for Relapse Prevention and Reducing HIV Risk. J Neuroimmune Pharmacol 11:401-7
Van Horn, Deborah H A; Drapkin, Michelle; Lynch, Kevin G et al. (2015) Treatment choices and subsequent attendance by substance-dependent patients who disengage from intensive outpatient treatment. Addict Res Theory 23:391-403
Franklin, Teresa R; Jagannathan, Kanchana; Wetherill, Reagan R et al. (2015) Influence of menstrual cycle phase on neural and craving responses to appetitive smoking cues in naturally cycling females. Nicotine Tob Res 17:390-7
Kampman, Kyle M; Lynch, Kevin G; Pettinati, Helen M et al. (2015) A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. Drug Alcohol Depend 155:105-10
Goldman, Marina; Ehrman, Ronald N; Suh, Jesse J et al. (2015) Brief report: ""spiders-No, puppies-Go"", introducing a novel Go NoGo task tested in inner city adolescents at risk for poor impulse control. J Adolesc 38:45-8
McKay, James R; Drapkin, Michelle L; Van Horn, Deborah H A et al. (2015) Effect of patient choice in an adaptive sequential randomization trial of treatment for alcohol and cocaine dependence. J Consult Clin Psychol 83:1021-32
Clarke, T-K; Crist, R C; Ang, A et al. (2014) Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J 14:303-8
Clarke, Toni-Kim; Weiss, Amy R D; Ferarro, Thomas N et al. (2014) The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction. Ann Hum Genet 78:33-9

Showing the most recent 10 out of 111 publications